CD163 and glioblastoma: Morphometric analysis (Figure 1B and Figure 2B) evidences the significantly increased numbers of CD68+ and CD163+ cells in the center of GBM tumors (CD68:16.53 ± 1.2%; CD163: 21.28 ± 0.4%) as compared to the CTRL (CD68: 10.66 ± 1.2%; CD163: 2.5 ± 1%).